Table 2. Most significant EOC risk associations by selection criteria outside of eleven known susceptibility regions.

					Pilot WGS Study		Case-control study data (13 sites)
Selection Criteria	Variant	Chr.	Position (hg19)	Location	EOC MAF	1000 GP MAF	Histology	Case MAF	Control MAF	N case, N control	OR (95%CI)	P value
WGS EOC+	rs138643956	10	79367857	Intron of KCNMA1	0.053	0.000	HGSC	0.004	0.001	3035, 5637	3.68 (1.79 - 7.55)	1.85 × 10−4
WGS EOC↑	rs117841616	20	57855211	20kb 5′ of EDN3	0.079	0.006	All	0.008	0.005	4973, 5634	1.93 (1.36 - 2.74)	2.06 × 10−4
WGS EOC↓	rs240783	6	100968737	Intron of ASCC3	0.184	0.494	HGSC	0.400	0.428	2956, 5518	0.89 (0.84 - 0.95)	7.90 × 10−4
WGS EOC−	rs9380516	6	35502202	10kb 5′ of RP3-340B19.3	0.000	0.155	HGSC	0.147	0.171	3027, 5633	0.83 (0.76 - 0.91)	6.44 × 10−5
NF-κB	rs10143322	14	91556577	24kb 5′ of C14orf159	n.a.	n.a.	All	0.220	0.246	4562, 5634	0.87 (0.82 - 0.93)	2.99 × 10−5
NF-κB	rs6092485	20	56045014	26kb 3′ of CTCFL	n.a.	n.a.	HGSC	0.335	0.311	3019, 5625	1.13 (1.05 - 1.21)	6.77 × 10−4
Endometrioid GWAS	rs9264042	6	31196801	25kb 3′ of HCG27	n.a.	n.a.	All	0.125	0.107	4440, 5505	1.17 (1.07 - 1.28)	4.71 × 10−4
Endometrioid GWAS	rs2638653	8	18666210	Intron of PSD3	n.a.	n.a.	EC	0.409	0.362	832, 5619	1.23 (1.11 - 1.37)	1.28 × 10−4

WGS, whole-genome sequencing; EOC, epithelial ovarian cancer; 1000 GP, 1000 Genomes Project; GWAS, genome wide association study; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; HGSC, high grade serous carcinoma; n.a., not applicable. WGS EOC+ variant selection criteria: MAF> 0% in serous EOC cases, monomorphic in 1000 GP European individuals; WGS EOC↑ variant selection criteria: polymorphic in cases and 1000 GP, MAF greater in WGS patients; WGS EOC↓ variant selection criteria: polymorphic in cases and 1000 GP, MAF greater in 1000 GP; WGS 1000 EOC− variant selection criteria: monomorphic in cases, MAF> 0% in 1000 GP.